Vireo Growth (VREOF) Assets Average (2021 - 2026)
Vireo Growth (VREOF) posted Assets Average of $873.0 million for Q1 2026, up 16.7% sequentially from $748.1 million in Q4 2025, and up 214.08% YoY from $278.0 million in Q1 2025.
Vireo Growth (VREOF) Assets Average (2021 - 2026) Analysis & Trends
Vireo Growth has reported Assets Average for 6 years, with the latest figure at $873.0 million in Q1 2026.
- Quarterly Assets Average rose 214.08% year-over-year to $873.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $873.0 million (up 214.08% YoY) and the FY2025 annual result came in at $548.0 million, up 137.18% from the prior year.
- Assets Average advanced to $873.0 million in Q1 2026 per VREOF's latest filing, from $748.1 million in the prior quarter.
- Over five years, Assets Average peaked at $873.0 million in Q1 2026 and troughed at $158.9 million in Q1 2023.
- A 5-year average of $304.7 million and a median of $187.1 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average slipped 3.02% in 2023, then surged 244.42% in 2025.
- Over 5 years, Assets Average stood at $166.2 million in 2022, then increased by 6.75% to $177.5 million in 2023, then jumped by 33.19% to $236.4 million in 2024, then jumped by 216.48% to $748.1 million in 2025, then climbed by 16.7% to $873.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $873.0 million, $748.1 million, and $669.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 5.97 Bn |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 1.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 873.00 Mn |
| Dec 31, 2025 | 748.06 Mn |
| Sep 30, 2025 | 669.13 Mn |
| Jun 30, 2025 | 468.19 Mn |
| Mar 31, 2025 | 277.95 Mn |
| Dec 31, 2024 | 236.37 Mn |
| Sep 30, 2024 | 194.27 Mn |
| Jun 30, 2024 | 192.78 Mn |
| Mar 31, 2024 | 187.07 Mn |
| Dec 31, 2023 | 177.47 Mn |
| Sep 30, 2023 | 168.81 Mn |
| Jun 30, 2023 | 162.29 Mn |
| Mar 31, 2023 | 158.89 Mn |
| Dec 31, 2022 | 166.24 Mn |
| Sep 30, 2022 | 171.07 Mn |
| Jun 30, 2022 | 164.78 Mn |
| Mar 31, 2022 | 163.85 Mn |
| Dec 31, 2021 | 165.57 Mn |
| Sep 30, 2021 | 138.42 Mn |
| Jun 30, 2021 | 118.06 Mn |